You are the owner of this page.
Edit Page
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
ChinaBio® Today
www.ChinaBioToday.com
ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.

News

< Previous 1 2 3 4 Next >
Zhaoke Acquires China Rights to Myopia Treatment in $102 Million Agreement
Zhaoke ( Hong Kong ) Ophthalmology Pharma acquired Greater China rights to a myopia treatment from Nevakar in a $102 million agreement. NVK-002 is a novel topical treatment aimed at slowing the... 
Beijing Immunochina Raises $15 Million for CAR-T Portfolio
Beijing Immunochina Pharma  raised $15 million in C+ round of financing to support its portfolio of 12 CAR-T candidates.  Established in 2015, Beijing Immunochina has developed a serum-free production... 
Beijing Immunochina Raises $15 Million for CAR-T Portfolio
Beijing Immunochina Pharma  raised $15 million in C+ round of financing to support its portfolio of 12 CAR-T candidates.  Established in 2015, Beijing Immunochina has developed a serum-free production... 
3DMed Completes $225 Million Round for Immunotherapy Candidates
3D Medicines, a Beijing clinical-stage biopharma, completed a $225 million funding. Two years ago, 3DMed spun off its diagnostics business into 3D Diagnostics and now concentrates on development of... 
Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement
Huadong Medicine in-licensed greater China rights to an antibody-drug conjugate developed by ImmunoGen in a $305 million agreement. IMGN853 (mirvetuximab soravtansine) is in a US Phase III trial for... 
Tickers IMGN
Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal
Deals and Financings Shanghai Curon Biopharma acquired China rights to a treatment for a novel lymphoma drug from Rhizen Pharma of Switzerland in a $149.5 million deal; EdiGene of Beijing raised $67... 
Tickers ASLN LGND LLY PPD
Week in Review: Curon Bio Acquires Lymphoma Drug Rights in $150 Million Deal
Deals and Financings Shanghai Curon Biopharma acquired China rights to a treatment for a novel lymphoma from Rhizen Pharma of Switzerland in a $149.5 million deal; EdiGene of Beijing raised $67 million... 
Tickers ASLN LGND LLY PPD
Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications
Singapore 's Aslan Pharma announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase (DHODH) inhibitor in autoimmune conditions, such as multiple sclerosis (MS). It will also test... 
Tickers ASLN MS
Qihan Biotech Applies Genome Editing to Create Allogenic Stem Cells
Qihan Biotech, a Hangzhou company applying genome editing to cell therapies and organ transplantation, has started a program to develop human stem cells with reduced immunogenicity. If successful, the... 
PPD Plans Major Suzhou Lab to Offer China Drug Development Services
PPD, a global CRO, announced plans to build a new laboratory in Suzhou to support China drug development. The 67,000-square-foot facility, which will offer bioanalytical, biomarker and vaccine... 
Tickers PPD
CBC Merges Two Shanghai Companies, AffaMed and EverInsight, into One
CBC Group (formerly C-Bridge Capital), a Singapore-Shanghai investor, merged two of its Shanghai portfolio companies, AffaMed Therapeutics and EverInsight Therapeutics, into a single entity under the... 
Tickers CNS
Cue Health Announces $481 Million Grant for Coronavirus Tests
Cue Health of San Diego was awarded a $481 million US Defense Department grant to ramp up production of its rapid point-of-care molecular coronavirus tests. In return for the grant, the US will receive... 
EdiGene Raises $67 Million for Clinical Trials of Gene Edited Drugs
China 's EdiGene raised $67 million in a Series B round to develop its genome editing technologies. The company is developing a portfolio of molecules aimed at genetic diseases and cancer, and it also... 
ImmuneOnco Completes $25 Million Funding for Immunotherapies
ImmuneOnco, a Shanghai oncology immunotherapy company, completed a $25 million Series B financing, led by Lilly Asia Fund. Founded in 2015, the company is developing bi-specific antibodies, novel... 
Tickers NK
Curon Announces $149.5 Million Deal for China Rights to Lymphoma Drug
Curon Biopharma, a Shanghai clinical-stage in-licensing company, acquired China rights to Tenalisib, a dual PI3K delta and gamma inhibitor, from Rhizen Pharma of Switzerland . Rhizen will receive... 
HitGen Pays $25 Million to Acquire Vernalis, a UK Discovery CRO, from Ligand
HitGen will acquire Vernalis Limited, a Cambridge , UK CRO, from Ligand Pharma for $25 million. HitGen, a Chengdu small molecule drug development CRO, said its operations are a good fit with Vernalis'... 
Tickers LGND
Innovent and Lilly Announce China Approval for Rituxan Biosimilar
Suzhou Innovent Bio and Eli Lilly announced their Rituxan biosimilar was approved in China for lymphoma and leukemia indications. Halpryza® (rituximab injection) is Innovent's fourth mAb approved for... 
Tickers LLY
Ascletis Subsidiary OK'd to Start US Trials of NASH Candidate
An Ascletis Pharma subsidiary, Gannex Pharma, was approved to begin US clinical trials of its novel candidate for non-alcoholic steatohepatitis (NASH). Developed in-house, ASC42 is a non-steroidal,... 
Tickers FXR
Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics
Last week, ReadCoor, a Boston company that developed an In Situ sequencing technology, was acquired by10x Genomics for $350 million. ReadCoor was backed by Decheng Capital, a Shanghai-Silicon Valley... 
Tickers TXG
Week in Review: $1.5 Billion Total in Week's China Deals
Deals and Financings   Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop eight assets in-licensed for China development; Genor Biopharma of Shanghai raised $371 million... 
Tickers CRVS LLY TXG
Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO
Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop its portfolio of eight assets in-licensed for China development. The company's stock climbed 32% in its first trading... 
Creative Bio of Guangzhou Raises $90 Million for Oncology Tests
reative Biosciences, a Guangzhou oncology testing company, raised $90 million in a  Series C funding led by Tsing Song Capital. In 2018, Creative Bio was approved by China's NMPA to market Colosafe, a... 
Fosun to Start US Trial of COVID-19 Antibody Treatment
Fosun Pharma was granted US FDA approval to begin clinical tests of an investigational COVID-19 antibody treatment, HLX70. The trial will be conducted by Hengenix Biotech, the California arm of Fosun's... 
Chengdu's Hinova Pharma Raises $147 Million for Novel Prostate, Gout Drugs
Hinova Pharmaceuticals, a Chengdu innovative drug company, closed a $147 million Series C round. The company said it would use the proceeds to conduct multi-center clinical trials and commercialize its... 
Junshi and Lilly to File for Emergency Use of Paired Antibodies for COVID-19
Junshi Bio of Shanghai and Lilly released positive interim data on their paired antibody treatment for COVID-19. In early results from a Phase II trial, the combination reduced viral load, symptoms and... 
Tickers LLY
Zai Lab Doses First Patient in China Trial of PD-1 for NSCLC
Zai Lab of Shanghai has dosed the first patient in a China Phase III trial of retifanlimab, an anti-PD-1 antibody, as a first line treatment for metastatic non-small-cell-lung cancer (NSCLC). In 2019,... 
Genor Completes $371 Million Hong Kong IPO; Market Cap Reaches $1.8 Billion
Genor Biopharma of Shanghai raised $371 million in its Hong Kong IPO, pricing the offering at the top of the range. In early trading, Genor rose 22%, giving the company a market capitalization of $1.8... 
Genor Completes $371 Million HK IPO; Market Cap Reaches $1.8 Billion
Genor Biopharma of Shanghai raised $371 million in its Hong Kong IPO, pricing the offering at the top of the range. In early trading, Genor rose 22%, giving the company a market capitalization of $1.8... 
10x Genomics Pays $350 Million to Acquire ReadCoor, a Spatial-Omics Company
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million. ReadCoor's technology measures large numbers of molecules directly in tissue while preserving the precise... 
Tickers TXG
Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy
Guangzhou Link Health Pharma and Shenzhen Pregene Biopharma announced a $65 million deal to acquire China/Asia rights to a cell therapy for bone fractures developed by Bone Therapeutics of Brussels .... 
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.